Inmune Bio, Inc. (INMB) · Oct 29, 2026 · Share issuance
$4.5M financing — 3.0M shares at $1.50 plus warrants for 3.0M shares at $1.65
INmune Bio’s financing brings in $4.5 million for general purposes, while matching warrants create a sizeable second wave of potential dilution.
INmune Bio is a late-stage biotech trying to move its cord-blood-derived Ebstrocel/CORDStrom platform toward regulatory approval while funding development of XPro for neuroinflammation and Alzheimer’s disease. Its cash balance was already declining, with $18.4 million reported at June 30, 2026 versus $24.8 million at year-end 2025.
This is a liquidity-supporting raise, not a business milestone. The company is selling 3.0 million shares for approximately $4.5 million gross, with proceeds earmarked for working capital and general corporate purposes. That gives INmune additional operating room as it advances regulatory and clinical programs, but the filing does not tie the money to a specific trial, approval submission, or commercial launch. The agreement says proceeds will be used “for working capital and general corporate purposes.” 〔0〕
| Offering | Terms | |
|---|---|---|
| Common shares (Offering terms) | 3,000,000 | $1.50 |
| Gross proceeds (published offering terms) | $4.50M | |
| Warrants (Purchase Agreement) | 3,000,000 | 100% of shares |
| Warrant exercise price (Purchase Agreement) | $1.65 | 5-year term |
| Warrant exercise date (Warrant) | April 27, 2027 | April 27, 2032 expiry |
The financing carries substantial future dilution. The warrants cover 100% of the shares sold, meaning the offering can ultimately expand the share count by another 3.0 million shares if exercised. The warrant package is less damaging than immediately issuing all of those shares because exercise is delayed until six months after issuance and the $1.65 strike is above the $1.50 purchase price, but existing holders still face a meaningful second layer of dilution. The filing states that the warrants are exercisable for “100% of the number of Shares purchased by the Purchaser.” 〔1〕
The news is largely confirmation rather than a fresh surprise. The financing terms were publicly announced on October 28, 2026, one day before this October 29 filing, so the market already knew the headline amount, share count, warrant coverage, and intended use of proceeds. The 8-K mainly formalizes the transaction and documents investor protections, including resale registration for the warrant shares within 30 days of closing. The filing says the company must file that registration statement “within thirty (30) calendar days of the Closing Date.” 〔2〕
Bottom line: The raise helps extend funding for INmune’s development and regulatory work, but it does so through immediate share issuance plus equal warrant coverage. It is financially useful but structurally dilutive, and the filing itself adds little beyond confirming terms already disclosed publicly.
Ebstrocel regulatory milestones and XPro development updates
A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.
A buy-side analyst on every ticker — the whole market decoded the second it moves, before it's a headline. Free gives you a taste. Pro takes the cap off and opens the full read on every company.
by Signing in NOW, claim your FREE 14-day Pro trial!